LY 2523199Alternative Names: 11beta-HSD1 inhibitor - Eli Lilly; LY2523199
Latest Information Update: 26 Jul 2013
At a glance
- Originator Eli Lilly
- Class Antihyperglycaemics
- Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 25 Jul 2013 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (unspecified route)